Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70.
The apoptosis stimulator STA-4783 acts by inducing expression of heat shock protein (Hsp)70 on tumor cell surfaces and disrupting the cytoskeletal network. Currently in development by Synta Pharmaceuticals for the potential treatment of solid tumors, phase II clinical trials in non-small-cell lung cancer, melanoma and sarcoma have been initiated.
Gehrmann
Mathias
M
University Hospital Regensburg, Dept. Hematology/Oncology, Molecular Oncology, H1 Carreras FoBau Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany. mathias.gehrmann@klinik.uni-regensburg.de
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D018840:HSP70 Heat-Shock Proteins / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D043823:Taxoids / Q000627:therapeutic use*; D050257:Tubulin Modulators / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D018840:HSP70 Heat-Shock Proteins; D006834:Hydrazines; D012333:RNA, Messenger; D043823:Taxoids; D050257:Tubulin Modulators; C080625:taxane; C512195:elesclomol